News

A two-day simulation-based course improved nurses’ readiness to treat obstetric crises linked to FNAIT and other complications.

The HLA/HPA Platelet Program at Canadian Blood Services, which serves patients with FNAIT, has seen an increased need for matched platelets.

A pregnant patient with a history of fetal death was diagnosed with chronic histiocyte intervillositis, which has characteristics similar to FNAIT.

Review of routine cord platelet testing found very few severe FNAIT cases, with most confirmed cases occurring in European infants.

Certain anti-HPA-1a antibodies can cause platelet aggregation through the FcγRIIa receptor, a mechanism that may contribute to FNAIT.

FNAIT antibodies attack platelets act in different ways, making it hard for doctors to predict how severe the disease may be in each patient.

Platelet unit storage time and mitochondrial DNA levels influenced inflammatory responses that could affect FNAIT complications.

Researchers found no anti–HPA-1a antibodies that bind only to αvβ3 in maternal blood from patients with FNAIT.

A targeted immunotherapy using a specially designed fusion protein for the treatment of FNAIT has shown early promise in animal models.

Biologics like nipocalimab will soon offer a targeted approach that could transform FNAIT prevention and management.